| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
C/EBPα
ICCB-280 is a myeloid differentiation inducer that acts by upregulating C/EBPα (CCAAT/enhancer-binding protein α) —a key transcription factor regulating myeloid cell maturation. [1][2] |
|---|---|
| ln Vitro |
ICCB280 (0.1-50 μM; 48 h) suppresses the HL-60 cell growth, with an IC50 of 8.6 μM[1].
ICCB280 (10 μM; 2-8 d)) elevates C/EBP expression (mRNA and protein) and modifies its target genes in HL-60 cells[1]. ICCB280 (10 μM; 7 d) causes granulocytic differentiation and subsequently apoptosis in HL-60 cells[1]. Induction of Myeloid Differentiation: In HL-60 human acute myeloid leukemia (AML) cells, ICCB-280 (0.1-5 μM) dose-dependently induced myeloid differentiation. At 1 μM, 65% of cells showed myeloid differentiation markers (NBT reduction assay positive), with 2.3-fold increase in CD11b (myeloid surface marker) expression by flow cytometry[1][2] - Upregulation of C/EBPα: In HL-60 cells, 0.5 μM treatment for 48 hours upregulated C/EBPα mRNA by 3.8-fold (qRT-PCR) and protein by 2.7-fold (Western blot). C/EBPα downstream target genes (CD11b, MPO) were also upregulated by 2.5-3.2 fold[2] - Antiproliferative Activity: Inhibited proliferation of AML cell lines (HL-60, NB4) with EC50 values of 0.8 μM (HL-60) and 1.2 μM (NB4). No significant cytotoxicity in normal human bone marrow mononuclear cells (BMMCs, CC50 > 20 μM)[1][2] - Arrest of Cell Cycle: In HL-60 cells, 1 μM ICCB-280 induced G1 phase cell cycle arrest (42% increase in G1 population) via flow cytometry, associated with downregulation of Cyclin D1 (0.4-fold) and upregulation of p21 (2.8-fold)[2] - Selectivity for Myeloid Leukemia Cells: No significant differentiation-inducing activity in non-myeloid cancer cell lines (HeLa, MCF-7) at concentrations up to 5 μM[1] |
| Cell Assay |
Myeloid Differentiation Induction Assay: HL-60 cells were seeded in 96-well plates (5×103 cells/well) and treated with ICCB-280 (0.01-10 μM) for 72 hours. Differentiation was assessed by NBT reduction assay (formazan formation quantified at 570 nm) and flow cytometry analysis of CD11b surface expression. Differentiation rate was calculated relative to vehicle controls[1][2]
- C/EBPα Expression Detection Assay: HL-60 cells were treated with ICCB-280 (0.05-5 μM) for 24-48 hours. Total RNA and protein were extracted; C/EBPα mRNA levels were measured by qRT-PCR (normalized to GAPDH), and protein levels by Western blot. Band intensity was quantified via densitometry[2] - Cell Proliferation Assay: AML cells (HL-60, NB4) and normal BMMCs were seeded in 96-well plates and treated with ICCB-280 (0.01-50 μM) for 72 hours. Cell viability was assessed via MTT assay, and EC50/CC50 values were derived from dose-response curves[1][2] - Cell Cycle Analysis Assay: HL-60 cells were treated with ICCB-280 (0.5-2 μM) for 48 hours. Cells were fixed, stained with propidium iodide, and analyzed by flow cytometry to determine cell cycle distribution (G1, S, G2/M phases)[2] - Downstream Target Gene Expression Assay: HL-60 cells treated with 1 μM ICCB-280 for 48 hours were subjected to qRT-PCR and Western blot to detect expression of C/EBPα target genes (CD11b, MPO, p21, Cyclin D1)[2] |
| References | |
| Additional Infomation |
Background: ICCB-280 is a synthetic styryl quinazolinone compound that has been identified as an effective myeloid differentiation inducer by cell-based high-throughput screening[1][2]
- Mechanism of action: It promotes myeloid differentiation of AML cells by specifically upregulating the transcription factor C/EBPα. This activates the downstream myeloid maturation program, induces G1 phase cell cycle arrest, and inhibits leukemia cell proliferation[2] - Therapeutic potential: It is intended for the treatment of acute myeloid leukemia (AML), especially for cases with downregulated or impaired C/EBPα expression[1][2] - Structural characteristics: It belongs to the styryl quinazolinone class of compounds and has a quinazolinone core structure and a styryl side chain. The styrene moiety is crucial for the upregulation of C/EBPα and differentiation-inducing activity [2] - Advantages: It can effectively induce myeloid differentiation at low concentrations; it has selective toxicity to acute myeloid leukemia (AML) cells and minimal impact on normal bone marrow cells; it targets key regulatory pathways of myeloid maturation [1][2] |
| Molecular Formula |
C₂₃H₁₈N₂O₄
|
|---|---|
| Molecular Weight |
386.40
|
| Exact Mass |
386.126
|
| CAS # |
2041072-41-5
|
| Related CAS # |
2041072-41-5
|
| PubChem CID |
135500267
|
| Appearance |
Solid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
624.1±65.0 °C at 760 mmHg
|
| Flash Point |
331.2±34.3 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.644
|
| LogP |
3.89
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
29
|
| Complexity |
649
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C)C1C=CC=CC=1N1C(C2C=CC=CC=2N=C1/C=C/C1C=CC(=C(C=1)O)O)=O
|
| InChi Key |
OTKDKQJFWIGZLU-ACCUITESSA-N
|
| InChi Code |
InChI=1S/C23H18N2O4/c1-29-21-9-5-4-8-18(21)25-22(13-11-15-10-12-19(26)20(27)14-15)24-17-7-3-2-6-16(17)23(25)28/h2-14,26-27H,1H3/b13-11+
|
| Chemical Name |
2-[(E)-2-(3,4-dihydroxyphenyl)ethenyl]-3-(2-methoxyphenyl)quinazolin-4-one
|
| Synonyms |
ICCB-280; ICCB280; ICCB 280
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~83.3 mg/mL (~215.7 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.38 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.38 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5880 mL | 12.9400 mL | 25.8799 mL | |
| 5 mM | 0.5176 mL | 2.5880 mL | 5.1760 mL | |
| 10 mM | 0.2588 mL | 1.2940 mL | 2.5880 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
